
Sign up to save your podcasts
Or


In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including a high-stakes Maine federal court hearing on the Health Resources and Services Administration's (HRSA) revamped 340B rebate pilot, efforts in Congress to block the rebate pilot before the end of the year and the result of a hospital lawsuit challenging Eli Lilly's 340B data requirements.
Key Topics Covered:
Maine Fed. Court Hearing Rematch on Rebates
Shannon, Will and Ted discuss the recent oral arguments before a Maine federal district court judge in an American Hospital Association-led lawsuit that aims to temporarily halt the Trump administration's new 340B rebate model pilot from taking effect on Jan. 1, 2027. Shannon notes how the Nov. 18 oral arguments compared to those in a similar 2025 lawsuit that went before the same federal judge. Will and Ted share their observations from the hearing and the three discuss what the judge's questions and comments to attorneys during the hearing could signal for hospitals' efforts to once again block HRSA's rebate pilot.
Congressional Efforts to Halt 340B Rebates
Luke breaks down a newly unveiled must-pass U.S. Senate spending bill and its accompanying explanatory statement that raises concerns over the 340B rebate model and drugmaker 340B contract pharmacy restrictions. He also details 340B provider groups' requests for a key bipartisan Senate group to include language in any year-end package that either delays or ends the 340B rebate model. Shannon discusses the potential implications of passing a continuing resolution versus a larger appropriations package, as well as how the Democrats' majority in the next Congress could affect future legislation come January.
340B Data Lawsuit Dismissed:
Will breaks down a Florida federal judge's recent ruling to dismiss a hospital lawsuit challenging Eli Lilly's in-house pharmacy 340B claims data requirements. He explains that the judge ruled that covered entities cannot use state law to enforce the 340B statute, citing a U.S. Supreme Court decision. Will also notes that two other hospitals have ongoing lawsuits against Lilly, and that multiple state attorneys general are pursuing enforcement actions against the Indiana-based drugmaker, as well.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care and reinvest in communities. We are very grateful to VytlOne for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode of our business podcast 340B Leaders Upfront, host Anna Mangum sits down with Mary Van Hoozer, General Manager at SunRx. SunRx is a leading healthcare technology company and 340B administrator.
Key Topics Covered:
Career Journey
Mary, who hails from Chicago and currently resides in Norfolk, Va. with her husband who serves in the Navy, describes her prior business roles with MedImpact (owner of SunRx), Cardinal Health and a specialty pharmacy. She outlines her entry into 340B in the early days of the program's shift to multiple contract pharmacies.
SunRx Partnerships with State Hospital Associations
Mary provides an overview of SunRx's ongoing partnerships with numerous state hospital associations, and the benefits of this model in facilitating collaboration among hospitals in addressing common 340B challenges. She also describes SunRx's roundtables, including their unique "kitchen table talks," where hospitals and other 340B covered entities (CEs) can exchange information and ideas with others in their region.
Command340B Platform
Mary outlines SunRx's Command340B™ platform, comprising six distinct solutions aimed at helping CEs address a variety of challenges: ACC340B™, Assist340B™, Edge340B™, Clear340B™, Certify340B™, and Transit340B™. Mary highlights how SunRx provides customized support for various types of CEs including health centers and hospitals. She also encourages all CEs to invest in building a strong, durable foundation for their 340B "house" so they can meet the increasing demands posed by developments such as the rebate model pilot and expanding claims and other reporting requirements.
Follow our Podcasts
Stay tuned for more episodes of 340B Leaders Upfront, which are posted monthly! Subscribe to 340B Leaders Upfront on your favorite podcast platform or YouTube.
Bonus: Listen to Inside 340B Report, our twice-monthly podcast, to get a behind-the-scenes window into the latest 340B news and developments from the journalists at 340B Report.
Special Offer for New 340B Report Subscribers First-time subscribers to 340B Report can use code PODCAST25 for 25% off when subscribing. Or contact us for a free 15-day trial to see why 340B Report is the indispensable source for 340B news and intelligence.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including two new Centers for Medicare and Medicaid Services (CMS) final rules with major 340B implications; what the 2026 congressional midterm elections could mean for the future of 340B policy; and CVS Health's surprise move to split off its businesses into two companies. Ted also reflects on Inside 340B Report's 50th episode milestone and thanks the behind-the-scenes team that makes sure listeners can benefit from this show.
Key Topics Covered:
CMS Releases Final Rules Affecting 340B
Will breaks down the new CMS rule to slash Medicare Part B reimbursement to certain types of 340B hospitals by around 32% starting next year. Ted looks back at the previous efforts to block the first Trump administration's Part B cuts and predicts there will be similar legal and legislative efforts this time as well. Will also explains CMS' other new rule creating a mandatory 340B data repository for Part D claims, including how it differs from other reporting requirements.
Congressional Bills and Midterm Outcomes
Shannon, Luke and Ted discuss the outcomes of the historic midterm elections and what they could mean for 340B policy on Capitol Hill in 2027. Shannon highlights key races in the U.S. House, while Luke breaks down the results from the U.S. Senate. Ted offers insights into what 340B observers could expect to see happen on the policy front in the 120th Congress. The three also discuss two recently introduced federal bills that would halt the Trump administration's 340B rebate model pilot from taking effect as planned on Jan. 1, 2027.
CVS Breaks Up
Will details CVS Health's recently announced move to split into two separate companies in 2028, and what that could mean for 340B stakeholders. He also notes that CVS' 340B practices have faced increasing scrutiny, including from a series of health system lawsuits alleging the company conspired to lower 340B contract pharmacy reimbursement owed to those hospitals. Will notes that CVS has denied those claims.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including legal challenges and legislation that aim to stop the Trump administration's 340B rebate model pilot from taking effect in January. They also discuss the upcoming midterm elections, and what they could mean for 340B policy; a U.S. House Democrat priorities memo that includes 340B-related actions; and the controversy surrounding Amgen's new healthcare encounter and services claims data requirements.
Key Topics Covered:
Actions to Halt the 340B Rebate Model Pilot
Will breaks down the American Hospital Association (AHA)-led lawsuit seeking to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot from taking effect on Jan. 1. He also discusses a federal judge's recent order allowing drug manufacturers to join the case as intervenors to defend the pilot. Meanwhile, Luke details the newly unveiled 340B Rebate Model Delay Act, a U.S. House bill which would delay the Trump administration's 340B rebate model pilot, or "any substantially similar" rebate program until Dec. 31, 2028.
Midterm Elections
Shannon and Ted preview how the Nov. 3 midterm elections could affect 340B policy. Shannon notes the lawmakers up for reelection who serve on the U.S. House and Senate committees overseeing 340B—and who could be tapped to lead those panels depending on the election outcomes. Ted breaks down how election analysts expect the midterms to go for each party and how a close U.S. Senate race in Kansas could affect 340B policy on Capitol Hill in the next Congress. Shannon also discusses U.S. House Democrats' top healthcare priorities for the 120th Congress, including a September letter lawmakers sent to House Minority Leader Hakeem Jeffries (D-N.Y.) that called for immediate actions to bolster the 340B program and halt the Trump administration's 340B rebate model pilot.
Amgen's New Requirements
Will details Amgen's new healthcare visit and service claims data requirements set to take effect in mid-November and explains why those requirements are more expansive than other drugmaker policies. Additionally, Luke discusses the National Association of Community Health Centers' letter asking HRSA to review the policy and direct Amgen to halt the requirements before they take effect next month.
340B Report's Midterm Webinar
Ted previews 340B Report's Nov. 10 subscriber-only webinar, which will dive into the midterm election results and what they mean for state and federal 340B policy in 2027 and beyond. He notes that the editorial team will also break down the major 340B changes on the horizon, including the latest news on the 340B rebate model and its legal challenges. Subscribers can learn more and register for the webinar by logging into 340B Report. Prospective subscribers can learn more about this exciting event by visiting 340B Report and taking advantage of a 25% discount on subscriptions. They can then benefit from all our must-watch webinars and other valuable services available only to subscribers.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, Verity Solutions. Verity Solutions' innovative, award-winning 340B program management solutions are designed to optimize 340B pharmacy spend and maximize pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including the newly-approved manufacturer 340B rebate pilot plans. They also discuss a new multi-organization community health center letter to Congressional leadership shared exclusively with 340B Report; the Pharmaceutical Research and Manufacturers of America's (PhRMA) new CEO; a 340B child site litigation update; and two 340B developments in the states.
Key Topics Covered:
HRSA's Rebate Pilot Plans Will breaks down the Health Resources and Services Administration's (HRSA) recently approved manufacturer 340B rebate pilot plans. He also explains why two drugmakers may have chosen not to include their eligible drugs in the pilot. Meanwhile, Luke details a new letter from more than 50 community health center associations representing over 1,500 health centers asking certain U.S. House leaders to hold a hearing on the "impending implementation" of the 340B rebate model pilot.
PhRMA's New Leader Luke discusses PhRMA's new President and CEO Eric Cantor, who formerly served in Congress as the House Majority Leader for Republicans from 2011 to 2014. Cantor was not active in 340B policy during his time on the Hill, but usually backed the drug industry in other policy areas. Ted provides his take on PhRMA's choice during the current political environment.
340B Child Site Ruling Appeal Will explains the latest in HRSA's appeal of a Washington, D.C., federal court ruling that struck down the agency's 340B hospital offsite clinic registration policy. He breaks down why the ruling was a victory for hospitals, as well as why both HRSA and PhRMA are arguing the ruling should be overturned. Will also discusses an amicus brief from four manufacturers taking a different approach.
State 340B Updates Luke breaks down two new similar bills introduced in each chamber of the Pennsylvania legislature. Both bills would prohibit manufacturers from restricting delivery of 340B drugs to covered entities or their contract pharmacies and ban 340B claims data requirements not required under federal law, among other changes. Will then breaks down an Arkansas' federal judge's ruling in favor of that state's 340B contract pharmacy access law, and the history of that state's litigation.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: 340B Report's scoop that the Trump administration is reportedly planning to shift 340B oversight to the U.S. Centers for Medicare and Medicaid Services (CMS); reactions to a proposal to slash Medicare Part B reimbursement for 340B hospitals; two major 340B legal developments; and a recap of 340B Report's latest webinar.
Key Topics Covered:
Shifting 340B Oversight?
Will details 340B Report's recent news alert reporting that the Trump administration plans to shift 340B oversight from its longtime home at the Health Resources and Services Administration (HRSA) to CMS this month. HRSA and CMS have not confirmed the report, which was based on a conversation with a source familiar with the plans. Will also explains why many 340B providers are concerned with the potential shift.
Competing Takes on 340B Hospital Cuts
Shannon discusses concerns 340B hospitals and New York congressional Republicans raised in public comments on CMS' proposed 2027 Hospital Outpatient Prospective Payment System rule, which would cut Medicare Part B reimbursement for 340B-acquired outpatient drugs. Meanwhile, Luke and Ted note that other stakeholders—including a private oncology practice group and a trade association of for-profit hospitals—have supported the move.
340B in the Courts
Will breaks down two recent federal district court rulings dismissing manufacturer challenges to Colorado's 340B access law. He also shares an update on Sanofi's ongoing lawsuit against HRSA seeking providers' pharmacy services agreements. Will notes that HRSA has recently contacted multiple providers about these contracts, which Sanofi argues could reveal that covered entities transfer the title of 340B drugs to contract pharmacies in violation of the 340B statute.
340B Report's New Explainer
Luke gives kudos to the editorial team on their recent webinar covering the 340B program's history and major tension points for both subscribers and nonsubscribers. He also discusses 340B Report's new explainer, which breaks down 340B program history, operations, oversight, key tension points and other important details.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, PharmaForce. PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: a key development in AbbVie's lawsuit challenging the Health Resources and Services Administration's (HRSA) 340B patient definition; potential candidates to become the next leader of an influential drug industry trade group; a new federal bill that would temporarily maintain 340B hospital eligibility; and the latest on the 340B rebate model pilot.
Key Topics Covered:
Providers Have a Say in Patient Definition Suit
Will breaks down a Washington, D.C. federal judge's recent ruling allowing three national 340B provider groups to intervene inAbbVie's lawsuit challenging HRSA's 340B patient definition. He explains that, as intervenors, the groups will defend HRSA's definition and can participate in briefings and hearings, and potentially appeal any decisions. Will notes that the outcome of the case could have major 340B program implications, and discusses how it relates to a prior provider lawsuit involving HRSA's patient definition.
Who Will Lead PhRMA?
Shannon discusses the former Republican policymakers Pharmaceutical Research and Manufacturers of America (PhRMA) is reportedly considering to replace its outgoing President and CEO Stephen Ubl. She notes that they include: former U.S. Reps. Greg Walden (R-Ore.), who previously chaired the House Energy and Commerce Committee, and Eric Cantor (R-Va.), former Louisiana Gov. Bobby Jindal (R) and former Centers for Medicare and Medicaid Services (CMS) AdÂminÂisÂtraÂtor Seema VerÂma. She and Ted reflect on the candidates' past records on 340B issues, while Ted offers some historical context on previous lawmakers that the big drug industry trade groups have selected to lead their organizations. He also speculates on what PhRMA might do this time.
New 340B Hospital Bill
Luke details a new bill aimed at addressing hospital concerns that recent Medicaid cuts in the "big beautiful bill" could cause some hospitals to lose 340B eligibility. U.S. Rep. Hillary Scholten (D-Mich.) introduced the bill, which would temporarily maintain 340B eligibility for certain hospitals if their disproportionate share hospital (DSH) adjustment percentage falls below the required threshold.
Latest on the Rebate Model
Will discusses the latest in HRSA's revised 340B rebate model pilot set to take effect on Jan. 1, 2027. He notes that drugmaker rebate plan applications were due Aug. 24, and that HRSA said it plans to announce approvals on Sept. 24. Will also speculates that any provider litigation challenging the rebate pilot is likely months away, as last year's successful hospital lawsuit was not filed until December 2025.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, NuvemRx. NuvemRx empowers covered entities to turn 340B from a compliance burden into a strategic asset with a full suite of TPA, in-house pharmacy and referral solutions. Learn more at www.nuvemrx.com. We are very grateful to NuvemRx for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: the Health Resources and Services Administration's (HRSA) newly unveiled 340B rebate pilot; the introduction of the long-anticipated bipartisan Senate SUSTAIN 340B Act; and a new 340B Report analysis on how lower list prices are impacting 340B savings.
Key Topics Covered:
Rebate Model 2.0
Will breaks down the details of HRSA's revised 340B rebate pilot, which is scheduled to take effect Jan. 1, 2027, and apply to drugs subject to Medicare price negotiations for the 2026 and 2027 cycles. Shannon notes that provider groups panned the policy, arguing it would undermine their ability to serve vulnerable patients, while the drug industry praised it and say it is a step toward program transparency. Will explains that the new pilot appears on stronger legal footing than the agency's first attempt that was blocked in federal court. However, he notes, another lawsuit is still likely.
Meanwhile, On Capitol Hill
Shannon discusses the long awaited Senate "Group of 6's" newly introduced SUSTAIN 340B Act. She notes that the 97-page bill would codify the use of contract pharmacies, end the 340B rebate model within one year and establish a neutral data clearinghouse, among other reforms.. Luke dives into his reporting on how stakeholders reacted to the bill and Ted provides information on what he is hearing from one of the key stakeholder groups.
Reduced WAC Prices Impacting Covered Entities
Luke discusses his reporting on how lower wholesale acquisition costs (WAC) are impacting 340B revenue for covered entities. He explores how new policies, like the Medicare drug price negotiations and new Medicare inflationary penalties, are leading some drugmakers to lower their list prices, and in turn reducing providers' 340B savings. Luke notes that some covered entities have already seen a decrease of $1 million so far in 2026, which translated into less wraparound services for patients.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, CompassRx. CompassRx is the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. We are very grateful to CompassRx for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Editor-in-Chief Will Newton joins Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a new Arkansas state lawsuit against 13 drugmakers and Second Sight Solutions; a key U.S. senator's recent comments on the program and new federal 340B lobbying data; and an update on the Health Resources and Services Administration's (HRSA) latest efforts to implement a controversial 340B rebate pilot.
Key Topics Covered:
Arkansas Files Suit
Will breaks down Arkansas Attorney General Tim Griffin's (R) new lawsuit against 13 drugmakers and drug industry vendor Second Sight Solutions for allegedly violating the state's 340B access law. He details Griffin's press conference announcing the lawsuit, where he predicted it would become a "billion-dollar case" while surrounded by state 340B providers and advocates. Luke notes that AstraZeneca exempted Louisiana covered entities from its contract pharmacy restrictions after a court declined it and other drugmakers' request for a rehearing in a case relating to that state's contract pharmacy access law.
Meanwhile, On Capitol Hill
Shannon discusses U.S. Sen. Bill Cassidy's (R-La.) latest comments on the 340B program during a recent Senate Health, Education, Labor and Pensions (HELP) Committee markup. Cassidy, a vocal 340B critic who chairs the HELP Committee, cautioned that an amended version of legislation to cap monthly insulin costs at $35 and create a pilot program to help states provide affordable insulin to uninsured patients could give "cover for 340B entities which are not using the [340B] program" the way Congress intended. Shannon also breaks down the latest 340B federal lobbying data, including what groups spent the most during the second quarter of 2026.
Rebate Model Update
Will offers that it seems like a matter of when, not if, HRSA will release its new 340B rebate pilot notice. He notes that White House regulators recently held their last scheduled meeting on the proposal, which remains under regulatory review. Will also explains that providers continue to oppose 340B rebates and dispute HRSA's assessment of its burden. He then breaks down a recent federal appeals court decision that upheld HRSA's authority over 340B rebates, while rejecting drugmakers' claims that they could implement rebates without prior approval.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, Visante. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. We are very grateful to Visante for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a trio of congressional 340B proposals; potential steep Medicare Part B cuts for 340B hospitals; and a new provider lawsuit challenging Eli Lilly's move to cut off 340B pricing.
Key Topics Covered:
Three Major 340B Legislative Proposals
Shannon, Luke and Ted discuss three new 340B-related proposals in Congress. Shannon breaks down U.S. Sen. Bill Cassidy's (R-La.) recently unveiled 340B discussion draft, which proposes several changes to the drug discount program that largely drew pushback from 340B provider advocates and support from the drug industry. Cassidy, who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, will leave Congress at the end of 2026. Shannon also discusses the U.S. House Ways & Means Committee's recent markup of a bill that would require certain hospitals to report 340B-related information on federal tax forms. Luke discusses a new bipartisan House bill that would also make several changes to the 340B program, but received mixed reactions from stakeholders. Ted offers insight on the various proposals, including how stakeholders have reacted to them.
CMS Eyes Steep Cuts for 340B Hospitals
Will breaks down the Centers for Medicare & Medicaid Services' (CMS) proposal to cut Medicare Part B reimbursement for 340B hospitals by nearly 37%. He notes that CMS argues the effort will save taxpayers money, while hospitals contend it will undermine the 340B program's purpose of expanding access and services for vulnerable patients. Will also explains that CMS attempted to cut Part B reimbursement during the first Trump administration—before the U.S. Supreme Court unanimously overturned that effort on procedural grounds.
Florida Hospital Sues Lilly Over 340B Data Reqs
Will details a Florida teaching hospital's recent federal lawsuit challenging Lilly's move to cut off 340B pricing for failure to comply with the drugmaker's new 340B in-house pharmacy claims data requirements. He notes that more provider lawsuits are likely to follow, but explains that covered entities can face legal obstacles when attempting to directly sue drugmakers under 340B.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, Proximity. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to [email protected]. We are very grateful to Proximity for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.